ReviewFrontiers in oncology2019
Turning the Tide Against Regulatory T Cells.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 55 citations in OpenAlex.
- Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.Nature communications · 2026Article
- Review
- Article
- Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.ACS pharmacology & translational science · 2024Review
- Review
- Systemic Delivery of Paclitaxel by Find-Me Nanoparticles Activates Antitumor Immunity and Eliminates Tumors.ACS nano · 2024Article
- Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect.British journal of cancer · 2023Review
- Article
- Age-associated remodeling of T cell immunity and metabolism.Cell metabolism · 2023Review
- Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease.Pharmaceutics · 2022Review
- Revisiting the melanomagenic pathways and current therapeutic approaches.Molecular biology reports · 2022Review
- A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer.Cancers · 2022Article
- Protean role of epigenetic mechanisms and their impact in regulating the Tregs in TME.Cancer gene therapy · 2022Article
- Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.Leukemia · 2022Article
- Tumors and Cytomegalovirus: An Intimate Interplay.Viruses · 2022Review
- Overproduction of IFNγ by Cbl-b-Deficient CD8+ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity.Cancer immunology research · 2022Article
- On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary.Frontiers in immunology · 2022Article
- Obesity modulates the immune macroenvironment associated with breast cancer development.PloS one · 2022Article
- The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.Frontiers in pharmacology · 2022Review
- CD8Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T (Treg) cells play crucial roles in health and disease through their immunosuppressive properties against various immune cells. In this review we will focus on the inhibitory role of Treg cells in anti-tumor immunity. We outline how Treg cells restrict T cell function based on our understanding of T cell biology, and how we can shift the equilibrium against regulatory T cells. To date, numerous strategies have been proposed to limit the suppressive effects of Treg cells, including Treg cell neutralization, destabilizing Treg cells and rendering T cells resistant to Treg cells. Here, we focus on key mechanisms which render T cells resistant to the suppressive effects of Treg cells. Lastly, we also examine current limitations and caveats of overcoming the inhibitory activity of Treg cells, and briefly discuss the potential to target Treg cell resistance in the context of anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.